The Lysosome: An amazing career development!

From a waste bag to a central signalling hub

This webinar is now on demand!
Fill the form below to receive webinar video link directly to your inbox.

    Webinar Summary:

    In the early 1950s, Christian De Duve coined the term “lysosome” to describe a cellular structure he referred to as the cell’s “suicide bag” (de Duve, 2005). However, over the span of seventy years, the lysosome has far surpassed its initial characterization and made a great career progression since then. More than 50 lysosomal storage diseases have been identified demonstrating the critical role of specific lysosomal proteins and their deficiencies or malfunctions. Moreover, recent investigations have uncovered a lysosome-to-nucleus signalling pathway and a network of lysosomal genes that orchestrate cellular clearance and energy metabolism. These findings underscore the lysosome’s multifaceted importance in cellular homeostasis and disease pathology as evidenced in cancer, obesity, neurodegenerative diseases, but also in the aging process.
    In this webinar Mattia Saggioro will illustrate the applications of image-based technologies to study lysosomal functions in disease relevant cellular models, whereas Manuel Paina will share how to study lysosomal located ion channels applying electrophysiological methods on isolated lysosomes.


    Lysosome, imaging, cell painting, HCS, pH-sensors, neurodegenerative diseases, oncology, organellar electrophysiology, lysosomal ion channels, Two-Pore-Channels, protein degradation, TFEB, autophagy, mitophagy, aging.


    • Stefan Lohmer, CEO, Axxam

    • Manuel Paina, Organellar Electrophysiology Supervisor, Axxam
    • Mattia Saggioro, Scientist, High Content Screening, Axxam

    Stefan Lohmer is co-founder and Chief Executive Officer of Axxam since 2001. Prior to founding Axxam, he was the Director of Bayer’s Research Centre in Milan (Italy) and the Head of Genomics worldwide for Bayer AG. In this function Stefan was responsible for generating and managing Bayer’s external genomic alliance with Millennium Pharmaceuticals (Cambridge, USA). He joined Bayer at the corporate research center located at Wuppertal (Germany) in 1992. Stefan holds a degree in Molecular Biology and Biochemistry from the Albertus Magnus University in Cologne (Germany) and completed his PhD at the Max-Planck-Institute for Plant Breeding in Cologne. He is an inventor on more than 20 patents and has authored more than 20 peer-reviewed publications. Stefan serves on the Board of Directors for Rewind Therapeutics, Libra Therapeutics, and Golgi Neurosciences as well being an Observer on the Board of Acousia Therapeutics.
    Stefan is passionate about transformative science and creating companies. “Never follow the path, always set the trail!”

    Manuel Paina is an electrophysiologist with several years of experience in both manual and automated patch-clamp platforms, applied to a large panel of ion channels. He obtained a PhD from the University of Milan, where he investigated the biophysical and pharmacological role of HCN4 channels in pacemaking. During a two-year postdoctoral stint at the University of Milan, he investigated mutations in the sodium channel NaV1.5. He joined Axxam in 2018, where he began working with automated patch-clamp platforms, and specialized in organellar electrophysiology, to perform patch-clamp experiments on ion channels expressed on nuclear, lysosomal and mitochondrial membranes.

    Mattia Saggioro graduated in Industrial biotechnology at the University of Padua, Italy. He holds a PhD in Developmental Medicine and Healthcare Planning Sciences during which he worked on a project on development and characterization of three-dimensional culture systems for cancer biology. He spent part of his PhD in the Tissue Engineering group at the Biomedicine Department in Basel, deepening his knowledge on the usage of perfusion bioreactors in 3D cell cultures. He then worked as a post-doc at Lund University, Sweden, applying imaging techniques to study the role of microtubules in cell nucleus deformation, in the context of cancer cell migration. Mattia joined Axxam in 2022 in the High Content Unit under the lead of Fernanda Ricci.

    Scroll to Top